Silibinin (an ingredient in Milk Thistle): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

27 March 2024

  • curprev 13:5713:57, 27 March 2024‎ Lazy talk contribs‎ 2,359 bytes −3‎ No edit summary
  • curprev 13:5613:56, 27 March 2024‎ Lazy talk contribs‎ 2,362 bytes +2,362‎ Created page with "{{TreatmentInfo |drug_name=Silibinin (Silymarin) |FDA_approval=No |used_for=Liver and biliary disorders, adjunct agent in cancer treatment |clinical_trial_phase=Investigated primarily in hepatitis and cirrhosis; small studies in cancers such as acute lymphoblastic leukemia, prostate cancer, breast cancer, head and neck cancer, and hepatocellular carcinoma |common_side_effects=Few reported; mainly gastrointestinal disturbances |OS_without=Not specified |OS_with=Not specif..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Silibinin_(an_ingredient_in_Milk_Thistle)"